Latest Drugs, Latest Approval in NNRTIs

What are NNRTIs?

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are antiviral agents that bind non-competitively to HIV-1’s reverse transcriptase and prevents viral RNA conversion to DNA. They are used to treat human immunodeficiency virus (HIV infection) and acquired immune deficiency syndrome (AIDS).

Name Updated
Etravirine (Etravirine [ e-tra-vir-een ]) 16-Aug-2023
Doravirine (Doravirine [ dor-a-vir-een ]) 14-Aug-2023
Nevirapine (Nevirapine [ ne-vye-ra-peen ]) 14-Aug-2023
Rilpivirine (Rilpivirine [ ril-pi-vir-een ]) 12-Aug-2023
Efavirenz (Efavirenz [ e-fav-ir-enz ]) 11-Aug-2023
Sustiva (Efavirenz [ e-fav-ir-enz ]) 05-Aug-2023
Viramune xr (Nevirapine [ ne-vye-ra-peen ]) 14-Jul-2023
Viramune (Nevirapine [ ne-vye-ra-peen ]) 14-Jul-2023
Pifeltro (Doravirine [ dor-a-vir-een ]) 13-Jul-2023
Intelence (Etravirine [ e-tra-vir-een ]) 13-Jul-2023
Edurant (Rilpivirine [ ril-pi-vir-een ]) 13-Jul-2023